Progyny (NASDAQ:PGNY) Releases FY 2026 Earnings Guidance

Progyny (NASDAQ:PGNY) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 2.040-2.100 for the period, compared to the consensus earnings per share estimate of 1.860. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion. Progyny also updated its Q3 2026 guidance to 0.500-0.520 EPS.

Analyst Ratings Changes

PGNY has been the subject of several research reports. Citizens Jmp lifted their target price on Progyny from $30.00 to $31.00 and gave the stock a “market outperform” rating in a research report on Monday, May 11th. Leerink Partners set a $38.00 price target on Progyny in a research report on Wednesday, July 22nd. Bank of America raised their price objective on Progyny from $29.00 to $31.00 and gave the stock a “buy” rating in a research note on Tuesday, June 2nd. Barclays reaffirmed an “equal weight” rating and set a $34.00 target price (up from $27.00) on shares of Progyny in a report on Tuesday, July 28th. Finally, Wall Street Zen lowered Progyny from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 25th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Progyny presently has a consensus rating of “Moderate Buy” and an average price target of $33.25.

Progyny Trading Down 3.7%

NASDAQ:PGNY traded down $1.16 during mid-day trading on Thursday, hitting $30.21. The stock had a trading volume of 1,863,949 shares, compared to its average volume of 1,465,451. The stock has a market capitalization of $2.37 billion, a price-to-earnings ratio of 39.23, a P/E/G ratio of 2.50 and a beta of 1.01. The company has a 50 day simple moving average of $28.93 and a 200-day simple moving average of $23.36. Progyny has a 52 week low of $16.10 and a 52 week high of $33.06.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, August 6th. The company reported $0.55 EPS for the quarter, topping the consensus estimate of $0.33 by $0.22. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The firm had revenue of $350.51 million during the quarter, compared to analysts’ expectations of $348.63 million. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. As a group, equities research analysts anticipate that Progyny will post 1.19 earnings per share for the current year.

Progyny declared that its Board of Directors has initiated a stock buyback program on Tuesday, May 26th that allows the company to buyback $200.00 million in shares. This buyback authorization allows the company to repurchase up to 10.3% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its stock is undervalued.

Insiders Place Their Bets

In related news, COO Melissa B. Cummings sold 9,578 shares of the stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $25.00, for a total value of $239,450.00. Following the completion of the transaction, the chief operating officer directly owned 73,371 shares of the company’s stock, valued at $1,834,275. This represents a 11.55% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kevin K. Gordon sold 5,500 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $24.99, for a total value of $137,445.00. Following the completion of the sale, the director owned 9,318 shares in the company, valued at approximately $232,856.82. This represents a 37.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 36,916 shares of company stock worth $939,875. 9.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Progyny

A number of institutional investors and hedge funds have recently bought and sold shares of PGNY. Wellington Management Group LLP lifted its stake in Progyny by 260.9% during the fourth quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after purchasing an additional 1,621,688 shares during the last quarter. Loomis Sayles & Co. L P bought a new position in shares of Progyny in the fourth quarter valued at $19,917,000. Ameriprise Financial Inc. increased its holdings in shares of Progyny by 37.6% in the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after buying an additional 545,431 shares in the last quarter. Norges Bank acquired a new stake in shares of Progyny during the 4th quarter valued at $10,167,000. Finally, Qube Research & Technologies Ltd boosted its stake in shares of Progyny by 161.6% during the 3rd quarter. Qube Research & Technologies Ltd now owns 457,015 shares of the company’s stock worth $9,835,000 after acquiring an additional 282,322 shares in the last quarter. Institutional investors own 94.93% of the company’s stock.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.